MADISON HEIGHTS, Mich. – May 2, 2014 – The Editorial Advisory and Securities Review Committee of BetterInvesting Magazine today announced Gilead Sciences, Inc. (NDQ: GILD) as its July 2014 “Stock to Study” and Microsoft Corporation (NDQ: MSFT) as its July 2014 “Undervalued Stock” for investors’ informational and educational use.
“The committee chose Gilead Sciences because of its outstanding growth potential owing to a successful new Hepatitis C medication and a promising pipeline,” said Adam Ritt, editor of BetterInvesting Magazine. “For the Undervalued selection, the committee cited Microsoft’s entry into the tablet market and move to a subscription base for its Office products as catalysts for the next two years.” Check BetterInvesting’s website in June for more details about these selections.
Committee members are Robert M. Bilkie, Jr., CFA; Daniel J. Boyle, CFA; Philip S. Dano, CFA; Donald E. Danko, CFA; Maury Elvekrog, CFA; Walter J. Kirchberger, CFA; Marisa Lenhard, CFA; and Paul McVey, CFA.
As stated, the BetterInvesting committee’s Stock to Study and Undervalued Stock choices are for the informational and educational uses of investors and are not intended as investment recommendations. BetterInvesting urges investors to educate themselves about the stock market so they can make informed decisions about stock purchases.
BetterInvesting is a national nonprofit organization that has been empowering individual investors since 1951. Founded in Detroit, the association (formerly known as National Association of Investors Corporation) was borne out of the conviction that anyone can become a successful long-term investor by following commonsense investing practices. BetterInvesting has helped more than 5 million people become better, more informed investors by providing webinars, in-person events, easy-to-use online tools for analyzing stocks, a monthly magazine and a community of volunteers and like-minded investors. For more information about BetterInvesting, visit its website at www.betterinvesting.org or call toll free (877) 275-6242.